We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Read MoreHide Full Article
Key Takeaways
Sales of Corcept's Cushing's syndrome drug Korlym rose 6.2% to $373.5 million in the first half of 2026.
CORT's Lifyorli generated $47.6 million in its first commercial quarter, offering a new revenue stream.
Lifyorli's approval adds a new commercial product as Corcept seeks to expand beyond its lead drug, Korlym.
Corcept Therapeutics (CORT - Free Report) remains focused on building long-term growth visibility beyond its lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome. The drug recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year.
Corcept has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Korlym is likely to remain an important contributor to Corcept’s top-line growth, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions. However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. A decline in the drug’s sales will significantly hinder the company’s prospects.
CORT Eyes Lifyorli to Potentially Lower Dependence on Korlym
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, we expect Lifyorli to help reduce CORT’s heavy dependence on Korlym over time.
Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Lifyorli in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.
A final decision from the European Commission is expected in the fourth quarter of 2026.
CORT’s Other Development Activities With Relacorilant
Relacorilant, in combination with other anticancer therapies, is also being studied in other solid tumors, including platinum-sensitive ovarian, prostate, endometrial, cervical and pancreatic cancers.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s (RHHBY - Free Report) Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Importantly, Corcept is also developing relacorilant, a selective glucocorticoid receptor antagonist for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
Successful clinical development and approval of relacorilant for additional indications could help Corcept establish additional revenue streams and reduce its dependence on Korlym.
View the Zacks #1 Rank List
Image: Bigstock
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Key Takeaways
Corcept Therapeutics (CORT - Free Report) remains focused on building long-term growth visibility beyond its lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome. The drug recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year.
Corcept has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Korlym is likely to remain an important contributor to Corcept’s top-line growth, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions. However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. A decline in the drug’s sales will significantly hinder the company’s prospects.
CORT Eyes Lifyorli to Potentially Lower Dependence on Korlym
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, we expect Lifyorli to help reduce CORT’s heavy dependence on Korlym over time.
Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Lifyorli in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.
A final decision from the European Commission is expected in the fourth quarter of 2026.
CORT’s Other Development Activities With Relacorilant
Relacorilant, in combination with other anticancer therapies, is also being studied in other solid tumors, including platinum-sensitive ovarian, prostate, endometrial, cervical and pancreatic cancers.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s (RHHBY - Free Report) Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Importantly, Corcept is also developing relacorilant, a selective glucocorticoid receptor antagonist for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
Successful clinical development and approval of relacorilant for additional indications could help Corcept establish additional revenue streams and reduce its dependence on Korlym.